According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion ...
Glutamate levels increase in early psychosis but normalize over time, challenging established perspectives on schizophrenia progression. The study involved treatment-naive patients, isolating natural ...
March 8, 2011 (Boston, Massachusetts) — Raltegravir (Isentress, Merck) is the antiretroviral drug of choice for treatment-naïve HIV-infected patients. Results from the QDMRK trial indicate that ...
Treatment-naive patients show greater BMD gains taking romosozumab than do patients who had previous antiresorptive treatments. "We conclude that prior antiresorptive therapy, particularly the ...
A groundbreaking sub-analysis presented at the Sexual Medicine Society of North America (SMSNA) Annual Meeting demonstrates the efficacy of a new treatment in two distinct patient populations. Materna ...
Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for ...
TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results